Industry News Archive

FDA approves nivolumab and relatlimab-rmbw for melanoma

On March 18, 2022, the U.S. Food and Drug Administration (FDA) approved nivolumab and relatlimab-rmbw for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

Read the FDA announcement.

Read Bristol Myers Squibb's announcement.

Posted 3/21/2022

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
Email Us